Work

Efficacy and safety of risperidone for attention deficit hyperactivity disorder and disruptive behaviour disorders: a systematic review and meta-analysis

Year: 2026

Type: article

Study designs: Systematic Review, Meta-Analysis

Abstract: OBJECTIVES: To quantitatively synthesise evidence from randomised controlled trials (RCTs) on the efficacy and safety of risperidone augmentation in children and adolescents with attention deficit hyperactivity disorder (ADHD) and comorbid disruptive behaviour disorders (DBDs). METHODS: PubMed, EMBASE, and Scopus were searched for studies published from inception to 14 February 2025 using combinations of the following terms: ADHD, DBD, risperidone, aggression, and RCTs. Included studies were RCTs that evaluated the efficacy and/or safety of risperidone as an adjunct to optimise stimulant therapy in individuals aged 6 to 12 years diagnosed with ADHD and comorbid DBDs. The primary outcome was change in aggression from baseline to post-intervention, measured using standardised scales, between the risperidone and placebo groups. Secondary outcomes included the tolerability of risperidone in terms of weight gain and increased serum prolactin levels. RESULTS: Three studies involving individuals aged 6 to 12 years with a dual diagnosis of ADHD and DBDs were included in the analysis. The overall sample size was 279, with 144 in the risperidone group and 135 in the placebo or active control (stimulant) group. Individuals receiving risperidone augmentation showed improvement in aggression (standardised mean difference [SMD] = -0.79, p < 0.001), greater weight gain (2.1 vs 0.5 kg, SMD = 0.22, p = 0.06), and higher serum prolactin levels (28.5 vs 2.3 ng/mL, SMD = 1.40, p < 0.001). CONCLUSION: Risperidone augmentation reduces aggression and oppositional symptoms in children and adolescents with ADHD and comorbid DBDs. Nonetheless, risperidone is associated with risks of weight gain, elevated serum prolactin, and metabolic syndrome.

Source: East Asian Archives of Psychiatry

DOI: 10.12809/eaap25137

Authors: Sravanthi Penubarthi, Karthikeyan Rajamanickam, Harsh Avinash Thappa, Rajesh Ayyalasomayajula, Pelluru Srinivasa Chakravarthy, Suchanshu Vats, Aanushka Suklabaidya, Siddharth Sarkar

Institutions: Post Graduate Institute of Medical Education and Research, Mahatma Gandhi Memorial Medical College, All India Institute of Medical Sciences Jodhpur, All India Institute of Medical Sciences

Language: English

Topic: Attention Deficit Hyperactivity Disorder

Subfield: Psychiatry and Mental health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: diamond

OpenAlex ID: W7147476946

FWCI:

Cites:

Cited by:

Related to: